Roles of histone deacetylases (HDACs) in epigenetic regulation: emerging paradigms from studies with inhibitors

Simple item page
dc.contributor.authorDelcuve, Genevieve P
dc.contributor.authorKhan, Dilshad H
dc.contributor.authorDavie, James R
dc.date.accessioned2012-04-27T05:27:53Z
dc.date.available2012-04-27T05:27:53Z
dc.date.issued2012-03-12
dc.date.updated2012-04-27T05:27:53Z
dc.description.abstractAbstract The zinc-dependent mammalian histone deacetylase (HDAC) family comprises 11 enzymes, which have specific and critical functions in development and tissue homeostasis. Mounting evidence points to a link between misregulated HDAC activity and many oncologic and nononcologic diseases. Thus the development of HDAC inhibitors for therapeutic treatment garners a lot of interest from academic researchers and biotechnology entrepreneurs. Numerous studies of HDAC inhibitor specificities and molecular mechanisms of action are ongoing. In one of these studies, mass spectrometry was used to characterize the affinities and selectivities of HDAC inhibitors toward native HDAC multiprotein complexes in cell extracts. Such a novel approach reproduces in vivo molecular interactions more accurately than standard studies using purified proteins or protein domains as targets and could be very useful in the isolation of inhibitors with superior clinical efficacy and decreased toxicity compared to the ones presently tested or approved. HDAC inhibitor induced-transcriptional reprogramming, believed to contribute largely to their therapeutic benefits, is achieved through various and complex mechanisms not fully understood, including histone deacetylation, transcription factor or regulator (including HDAC1) deacetylation followed by chromatin remodeling and positive or negative outcome regarding transcription initiation. Although only a very low percentage of protein-coding genes are affected by the action of HDAC inhibitors, about 40% of noncoding microRNAs are upregulated or downregulated. Moreover, a whole new world of long noncoding RNAs is emerging, revealing a new class of potential targets for HDAC inhibition. HDAC inhibitors might also regulate transcription elongation and have been shown to impinge on alternative splicing.
dc.description.versionPeer Reviewed
dc.identifier.citationClinical Epigenetics. 2012 Mar 12;4(1):5
dc.identifier.doihttp://dx.doi.org/10.1186/1868-7083-4-5
dc.identifier.urihttp://hdl.handle.net/1993/5326
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderDelcuve et al.; licensee BioMed Central Ltd.
dc.titleRoles of histone deacetylases (HDACs) in epigenetic regulation: emerging paradigms from studies with inhibitors
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
1868-7083-4-5.pdf
Size:
507.55 KB
Format:
Adobe Portable Document Format
Description:
Download
Thumbnail Image
Name:
1868-7083-4-5.xml
Size:
139.78 KB
Format:
Extensible Markup Language
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works